MIIP, also known as migration and invasion inhibitory protein, is a gene that functions as a tumor-suppressor in various cancers [3]. It plays a role in regulating multiple biological processes. MIIP is involved in pathways related to cell migration, invasion, and mitosis, and is associated with the cytoskeleton system, as it can regulate microtubules by interacting with HDAC6 [3].

In hepatocellular carcinoma (HCC), MIIP expression is decreased, and low MIIP expression is associated with distant metastasis and poor prognosis. MIIP can inhibit the malignant progression of HCC by regulating AKT expression [1]. In colorectal cancer, MIIP down-regulation drives cancer progression through inducing peri-cancerous adipose tissue browning. MIIP interacts with AZGP1, regulating its glycosylation and secretion, which in turn promotes adipose browning and CRC cell proliferation [2]. In triple-negative breast cancer, MIIP is a favorable prognostic indicator, inhibiting tumor angiogenesis, proliferation, and metastasis by interacting with ITGB3 and suppressing its downstream signaling [4]. In clear cell renal cell carcinoma, MIIP inhibits proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis [5]. In prostate cancer, MIIP inhibits EMT and cell invasion through the miR-181a/b-5p-KLF17 axis, and also inhibits growth via interaction with PP1α and negative modulation of AKT signaling [6,8]. In endometrial cancer, MIIP functions as a tumor suppressor, attenuating Rac1 signaling and remodeling the cytoskeleton to suppress metastasis [7]. In nasopharyngeal carcinoma, MIIP expression is associated with radiosensitivity [9]. In esophageal squamous cell carcinoma, MIIP expression is higher in cancer tissues than in paracancerous normal epithelia and is an independent prognostic factor [10].

In conclusion, MIIP plays a crucial role in inhibiting the progression of multiple cancers. Model-based research, especially gene knockout or knockdown experiments in cell lines as described in these studies, has revealed its role in regulating key cellular processes related to cancer development. Understanding MIIP's function provides potential targets for cancer treatment and prognosis prediction.

References:

1. Fang, J, Chen, Y-L, Yao, H-B, Yang, P, Ding, Z-Y. . MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT. In European review for medical and pharmacological sciences, 24, 2335-2346. doi:10.26355/eurrev_202003_20500. https://pubmed.ncbi.nlm.nih.gov/32196585/

2. Wang, Qinhao, Su, Yuanyuan, Sun, Ruiqi, Qiao, Qing, Li, Xia. 2024. MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning. In Cell & bioscience, 14, 12. doi:10.1186/s13578-023-01179-0. https://pubmed.ncbi.nlm.nih.gov/38245780/

3. Wang, Yingmei, Wen, Jing, Zhang, Wei. . MIIP, a cytoskeleton regulator that blocks cell migration and invasion, delays mitosis, and suppresses tumorogenesis. In Current protein & peptide science, 12, 68-73. doi:. https://pubmed.ncbi.nlm.nih.gov/21190522/

4. Gao, Yujing, Fang, Yujie, Huang, Yongli, Shan, Jingxuan, Li, Pu. 2022. MIIP functions as a novel ligand for ITGB3 to inhibit angiogenesis and tumorigenesis of triple-negative breast cancer. In Cell death & disease, 13, 810. doi:10.1038/s41419-022-05255-0. https://pubmed.ncbi.nlm.nih.gov/36130933/

5. Yan, Fengqi, Wang, Qinhao, Xia, Mingyuan, Wu, Guojun, Li, Xia. . MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis. In Cancer biology & medicine, 19, 818-35. doi:10.20892/j.issn.2095-3941.2020.0296. https://pubmed.ncbi.nlm.nih.gov/34931765/

6. Hu, Wei, Yan, Fengqi, Ru, Yi, Li, Xia, Wang, Qinhao. 2020. MIIP inhibits EMT and cell invasion in prostate cancer through miR-181a/b-5p-KLF17 axis. In American journal of cancer research, 10, 630-647. doi:. https://pubmed.ncbi.nlm.nih.gov/32195032/

7. Wang, Yingmei, Hu, Limei, Ji, Ping, Xue, Fengxia, Zhang, Wei. 2016. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. In Journal of hematology & oncology, 9, 112. doi:10.1186/s13045-016-0342-6. https://pubmed.ncbi.nlm.nih.gov/27760566/

8. Yan, Guang, Ru, Yi, Yan, Fengqi, Wang, Qinhao, Li, Xia. 2019. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling. In Cell communication and signaling : CCS, 17, 44. doi:10.1186/s12964-019-0355-1. https://pubmed.ncbi.nlm.nih.gov/31092266/

9. Zhou, Hong-Ping, Qian, Lu-Xi, Zhang, Nan, He, Xia, Yin, Li. 2018. MIIP gene expression is associated with radiosensitivity in human nasopharyngeal carcinoma cells. In Oncology letters, 15, 9471-9479. doi:10.3892/ol.2018.8524. https://pubmed.ncbi.nlm.nih.gov/29805670/

10. Wen, Jing, Liu, Qian-Wen, Luo, Kong-Jia, Hu, Yi, Fu, Jian-Hua. 2016. MIIP expression predicts outcomes of surgically resected esophageal squamous cell carcinomas. In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 10141-8. doi:10.1007/s13277-015-4633-2. https://pubmed.ncbi.nlm.nih.gov/26825982/